Just Published: "Slovakia Pharmaceuticals & Healthcare Report Q4 2015"

Eurozone recovery and an improving domestic economic outlook will provide a boost to healthcare expenditure in Slovakia in the short - term. Over the longer term, we expect healthcare spending to accelerate given Slovakia's ageing population and burden of chronic diseases. With public finances on firmer footing and a centre-left government promising more generous social spending, multinational drugmakers and medical device companies can expect to see growth in revenues from Slovakia.

Headline Expenditure Projections

Pharmaceuticals: EUR1.85bn (USD2.46bn) in 2014 to EUR1.91bn (USD2.30bn) in 2015; +3.5% in local currency terms and -6.6% in US dollar terms.
Healthcare: EUR6.13bn (USD8.15bn) in 2014 to EUR6.37bn (USD7.64bn) in 2015; 3.9% in local currency terms and -6.2% in US dollar terms.

Risk/Reward Index

Full Report Details at
- http://www.fastmr.com/prod/1047986_slovakia_pharmaceuticals.aspx?afid=301

Slovakia's Risk Index score indicates that the country has one of the best business environments in the Central and Eastern European region, although its ranking is moderated by its less-than-impressive Rewards score. Consequently, Slovakia has a Risk/Reward Index score of 56.4 out of 100, making it now the third-most attractive pharmaceutical market in Central and Eastern Europe.

Key Trends And Developments

The European Commission has recommended Slovakia streamline its public procurement process in the healthcare sector in order to strengthen competition and improve overall control. The recommendations are part of a so-called 'European Semester' under which the European Commission assesses the reform programmes of each member state. The commission also suggested Slovakia increase its investment in infrastructure and simplify the administrative procedures to obtain building permits. The recommendations are focused on areas considered essential from a macroeconomic point of view and the country should take action to address these recommendations in the next 12-18 months.

The Slovakia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovakia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovakia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovakia, to test other views - a key input for successful budgeting and strategic business planning in the Slovak pharmaceutical and healthcare market.
* Target business opportunities and risks in the Slovak pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015